4.7 Article

Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention-Related Myocardial Infarction

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 60, Issue 22, Pages 2296-2304

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2012.09.005

Keywords

angioplasty; cardiovascular; clinical trial; creatine kinase; diagnostic techniques; endpoint determination; myocardial infarction; surrogate endpoint

Funding

  1. Schering-Plough
  2. Sanofi-Aventis
  3. Merck, Inc.
  4. Bristol-Myers Squibb
  5. Schering-Plough Research Institute
  6. Eli Lilly Company
  7. Daiichi Sankyo
  8. Amylin
  9. JJ-Scios
  10. Merck/Schering Plough
  11. Novartis
  12. Bristol-Myers Squibb Foundation
  13. AstraZeneca
  14. diaDexus
  15. Eli Lilly Co.
  16. GlaxoSmithKline
  17. Murdock Study
  18. NHLBI
  19. Regado Biosciences, Inc.
  20. Roche
  21. Abbott Vascular
  22. Amgen Inc.
  23. Amylin Inc.
  24. Baxter
  25. Edwards Lifesciences
  26. Guidant Corp.
  27. Ikaria
  28. Johnson Johnson
  29. KAI
  30. Luitpold Pharmaceuticals
  31. Medtronic
  32. Portola Pharmaceuticals
  33. POZEN Pharmaceuticals
  34. Regado Biosciences
  35. Roche Diagnostic
  36. The Medicines Co.

Ask authors/readers for more resources

Objectives This study compared prognoses of myocardial infarction related to percutaneous coronary intervention (PCI, procedural MI) using increasing creatine kinase-myocardial band (CK-MB) thresholds with spontaneous MI. Background Procedural MI usually is defined by a CK-MB elevation of more than 3 times the upper limit of normal (ULN), but higher thresholds have been proposed. Methods Patients from the EARLY-ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) study and the SYNERGY (Superior Yield of the New strategy of Enoxaparin, Revascularization and GIYcoprotein IIb/IIIa inhibitors) study treated with PCI were included. The primary end point was 1-year all-cause mortality from 24 h after PCI. To determine an enzymatic threshold for procedural MI with a prognosis similar to that of spontaneous MI, we redefined procedural MI using increasing CK-MB thresholds and compared corresponding hazard ratios with those of spontaneous MI (CK-MB more than twice the ULN). Hazard ratios for mortality for procedural and spontaneous MI were calculated using Cox proportional hazards regression and Global Registry of Acute Cardiac Events covariates for risk adjustment. Results Nine thousand eighty-seven patients who underwent PCI (46.8%) were included; 773 procedural MI and 239 spontaneous MI occurred within 30 days. Adjusted hazard ratios for 1-year death were 1.39 (95% confidence interval [CI]: 1.01 to 1.89) for procedural MI and 5.37 (95% CI: 3.90 to 7.38) for spontaneous MI. The CK-MB threshold for procedural MI that achieved the same prognosis as spontaneous MI was 27.7 times the ULN (95% CI: 13.9 to 58.4), but this differed between the SYNERGY study (57.9 times the ULN, 95% CI: 17.9 to 63.6) and the EARLY-ACS study (20.4 times the ULN, 95% CI: 5.16 to 24.2). Of all procedural MI, 49 (6%) had CK-MB elevations of 27.7 or more times the ULN. Conclusions The current enzymatic definition of procedural MI (CK-MB more than 3 times the ULN) used in clinical trials is less strongly associated with death than that of spontaneous MI. Procedural MI achieves similar prognosis for 1-year mortality when much higher CK-MB thresholds are applied. (J Am Coll Cardiol 2012;60:2296-304) (C) 2012 by the American College of Cardiology Foundation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available